# Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

> **NCT03700294** · PHASE1 · TERMINATED · sponsor: **ADC Therapeutics S.A.** · enrollment: 18 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ADCT-601

## Key facts

- **NCT ID:** NCT03700294
- **Lead sponsor:** ADC Therapeutics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-21
- **Primary completion:** 2019-12-11
- **Final completion:** 2019-12-11
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Change in clinical plan and drug supply
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03700294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03700294, "Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03700294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*